BACKGROUND: Aberrant activation of signaling pathways downstream of epidermal growth factor receptor (EGFR) has been hypothesized to be one of the mechanisms of cetuximab (a monoclonal antibody against EGFR) resistance in head and neck squamous cell carcinoma (HNSCC). To infer relevant and specific pathway activation downstream of EGFR from gene expression in HNSCC, we generated gene expression signatures using immortalized keratinocytes (HaCaT) subjected to ligand stimulation and transfected with EGFR, RELA/p65, or HRASVal12D. RESULTS: The gene expression patterns that distinguished the HaCaT variants and conditions were inferred using the Markov chain Monte Carlo (MCMC) matrix factorization algorithm Coordinated Gene Activity in Pattern S...
While genetic alterations in Epidermal growth factor receptor (EGFR) and PI3K are common in head and...
Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS ...
The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of head and neck s...
BACKGROUND: Aberrant activation of signaling pathways downstream of epidermal growth factor receptor...
Abstract Background Aberrant activation of signaling pathways downstream of epidermal growth factor ...
Aberrant signal transduction pathways induce and main-tain many cancers [1-3]. Therefore, targeted t...
The epidermal growth factor receptor (EGFR) is widely expressed in head and neck squamous cell carci...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the United States a...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
KRAS mutation status is being used as the sole biomarker to predict therapeutic efficacy of cetuxima...
Head and neck squamous cell carcinoma (HNSCC) remains a deadly disease with poor prognosis. Developi...
Inhibition of epidermal growth factor receptor (EGFR) signaling has emerged as a novel therapeutic s...
AbstractOverexpression of the epidermal growth factor receptor (EGFR, ErbB1, HER1) is frequent in he...
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoc...
While genetic alterations in Epidermal growth factor receptor (EGFR) and PI3K are common in head and...
Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS ...
The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of head and neck s...
BACKGROUND: Aberrant activation of signaling pathways downstream of epidermal growth factor receptor...
Abstract Background Aberrant activation of signaling pathways downstream of epidermal growth factor ...
Aberrant signal transduction pathways induce and main-tain many cancers [1-3]. Therefore, targeted t...
The epidermal growth factor receptor (EGFR) is widely expressed in head and neck squamous cell carci...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the United States a...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
KRAS mutation status is being used as the sole biomarker to predict therapeutic efficacy of cetuxima...
Head and neck squamous cell carcinoma (HNSCC) remains a deadly disease with poor prognosis. Developi...
Inhibition of epidermal growth factor receptor (EGFR) signaling has emerged as a novel therapeutic s...
AbstractOverexpression of the epidermal growth factor receptor (EGFR, ErbB1, HER1) is frequent in he...
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoc...
While genetic alterations in Epidermal growth factor receptor (EGFR) and PI3K are common in head and...
Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS ...
The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of head and neck s...